1-(3-羟基-6-甲基吡啶-2-基)乙酮 | 1038399-45-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-羟基-6-甲基吡啶-2-基)乙酮
• 英文名称: 1-(3-Hydroxy-6-methylpyridin-2-yl)ethanone
• CAS: 1038399-45-9
• 化学式: C₈H₉NO₂
• 分子量: 151.165
• InChiKey: ZHXFIAWKTKFCKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-甲基-1H-吲唑-5-羧酸 、 1-(3-羟基-6-甲基吡啶-2-基)乙酮 、 N-叔丁氧羰基-4-哌啶酮 在 四氢吡咯 、 盐酸 作用下， 以 甲苯 、 1,4-二氧六环 为溶剂， 生成 6-methyl-1'-(7-methyl-1H-indazole-5-carbonyl)spiro[3H-pyrano[3,2-b]pyridine-2,4'-piperidine]-4-one
  参考文献：
  名称：

  Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2

  摘要：

  Screening Pfizer's compound library resulted in the identification of weak acetyl-CoA carboxylase inhibitors, from which were obtained rACC1 CT-domain co-crystal structures. Utilizing HTS hits and structure-based drug discovery, a more rigid inhibitor was designed and led to the discovery of sub-micromolar, spirochromanone non-specific ACC inhibitors. Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.091

文献信息

• N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2947082A1

  公开（公告）日：2015-11-25

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了一种式 (I) 的化合物 或该化合物的药学上可接受的盐，其中 R1、R2、R3 和 R4 如本文所述；其药物组合物；及其在治疗通过抑制动物体内乙酰-CoA 羧化酶调节的疾病、病症或失调中的用途。
• US7183278B1
  申请人：——

  公开号：US7183278B1

  公开（公告）日：2007-02-27
• [EN] N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE N1-PYRAZOLOSPIROCÉTONE ACÉTYL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2011058474A1

  公开（公告）日：2011-05-19

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.